AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
Cipla has partnered with ImmunoACT to introduce the CAR-T cell therapy 'talicabtagene autoleucel' in South Africa, Algeria, ...
Applied Cells Inc. and Immuneel Therapeutics Private Limited today announced that the companies have entered into a collaboration framework to jointly evaluate application of Applied Cells' MARS(R) ...
This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...
Looking to build a new laboratory or expand your existing facility. Talk to your Formaspace Design Consultant about our custom lab furniture solutions, built in the USA, at our Austin, Texas, factory ...
Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback